1. Wallin, MT, Culpepper, WJ, Campbell, JD, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology 2019; 92: e1029–e1040. 2019/02/17.
Google Scholar | Crossref | Medline2. Weiner, HL . The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009; 65: 239–248. 2009/04/01.
Google Scholar | Crossref | Medline | ISI3. Wattjes, MP, Rovira, A, Miller, D, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015; 11: 597–606. 2015/09/16.
Google Scholar | Crossref | Medline | ISI4. Sormani, MP, Bruzzi, P. MRI Lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol 2013; 12: 669–676. 2013/06/08.
Google Scholar | Crossref | Medline | ISI5. Barkhof, F . The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002; 15: 239–245. 2002/06/05.
Google Scholar | Crossref | Medline | ISI6. Healy, BC, Buckle, GJ, Ali, EN, et al. Characterizing clinical and MRI dissociation in patients with multiple sclerosis. J Neuroimaging 2017; 27: 481–485. 2017/03/07.
Google Scholar | Crossref | Medline7. Rogosnitzky, M, Branch, S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals 2016; 29: 365–376. 2016/04/08.
Google Scholar | Crossref | Medline | ISI8. https://www.fda.gov/Drugs/DrugSafety/ucm589213.htm (24 November 2021).
Google Scholar9. Giovannoni, G, Tomic, D, Bright, JR, et al. “No evident disease activity": the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler 2017; 23: 1179–1187. 2017/04/07.
Google Scholar | SAGE Journals | ISI10. Khalil, M, Teunissen, CE, Otto, M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018; 14: 577–589. 2018/09/02.
Google Scholar | Crossref | Medline11. Bhan, A, Jacobsen, C, Myhr, KM, et al. Neurofilaments and 10-year follow-up in multiple sclerosis. Mult Scler 2018; 24: 1301–1307. 2018/08/02.
Google Scholar | SAGE Journals | ISI12. Stilund, M, Gjelstrup, MC, Petersen, T, et al. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. PLoS One 2015; 10: e0119681. 2015/04/11.
Google Scholar | Crossref | Medline13. Norgren, N, Sundstrom, P, Svenningsson, A, et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004; 63: 1586–1590. 2004/11/10.
Google Scholar | Crossref | Medline | ISI14. Hakansson, I, Tisell, A, Cassel, P, et al. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur J Neurol 2017; 24: 703–712. 2017/03/07.
Google Scholar | Crossref | Medline | ISI15. Hakansson, I, Tisell, A, Cassel, P, et al. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. J Neuroinflammation 2018; 15: 209. 2018/07/20.
Google Scholar | Crossref | Medline16. Gaetani, L, Eusebi, P, Mancini, A, et al. Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. Mult Scler Relat Disord 2019; 35: 228–232. 2019/08/14.
Google Scholar | Crossref | Medline17. Varhaug, KN, Barro, C, Bjornevik, K, et al. Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm 2018; 5: e422. 2017/12/07.
Google Scholar | Crossref | Medline18. Jacobsen, C, Hagemeier, J, Myhr, KM, et al. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J Neurol Neurosurg Psychiatry 2014; 85: 1109–1115. 2014/02/21.
Google Scholar | Crossref | Medline | ISI19. Zivadinov, R, Heininen-Brown, M, Schirda, CV, et al. Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 2012; 59: 331–339. 2011/08/09.
Google Scholar | Crossref | Medline | ISI20. Smith, SM, Zhang, Y, Jenkinson, M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479–489. 2002/12/17.
Google Scholar | Crossref | Medline | ISI21. Patenaude, B, Smith, SM, Kennedy, DN, et al. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011; 56: 907–922. 2011/03/01.
Google Scholar | Crossref | Medline | ISI22. Petzold, A, Altintas, A, Andreoni, L, et al. Neurofilament ELISA validation. J Immunol Methods 2010; 352: 23–31. 2009/10/28.
Google Scholar | Crossref | Medline | ISI23. Tortorella, C, Direnzo, V, Ruggieri, M, et al. Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2018; 24: 1039–1045. 2017/05/26.
Google Scholar | SAGE Journals | ISI24. Khalil, M, Enzinger, C, Langkammer, C, et al. CSF Neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler 2013; 19: 436–442. 2012/08/25.
Google Scholar | SAGE Journals | ISI25. Eshaghi, A, Prados, F, Brownlee, WJ, et al. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol 2018; 83: 210–222. 2018/01/14.
Google Scholar | Crossref | Medline26. Minagar, A, Barnett, MH, Benedict, RH, et al. The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology 2013; 80: 210–219. 2013/01/09.
Google Scholar | Crossref | Medline | ISI27. Villar, LM, Picon, C, Costa-Frossard, L, et al. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. Eur J Neurol 2015; 22: 1169–1175. 2014/10/18.
Google Scholar | Crossref | Medline | ISI28. Burman, J, Zetterberg, H, Fransson, M, et al. Assessing tissue damage in multiple sclerosis: a biomarker approach. Acta Neurol Scand 2014; 130: 81–89. 2014/02/28.
Google Scholar | Crossref | Medline | ISI29. Rocca, MA, Barkhof, F, De Luca, J, et al. The hippocampus in multiple sclerosis. Lancet Neurol 2018; 17: 918–926. 2018/09/29.
Google Scholar | Crossref | Medline30. Reyes, S, Smets, I, Holden, D, et al. CSF Neurofilament light chain testing as an aid to determine treatment strategies in MS. Neurol Neuroimmunol Neuroinflamm 2020 Aug 21; 7 (6):e880 2020/08/23.
Google Scholar | Crossref31. Zecca, C, Disanto, G, Sormani, MP, et al. Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis. Mult Scler 2016; 22: 782–791. 2015/10/16.
Google Scholar | SAGE Journals | ISI32. Disanto, G, Barro, C, Benkert, P, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017; 81: 857–870. 2017/05/18.
Google Scholar | Crossref | Medline | ISI33. Kuhle, J, Barro, C, Disanto, G, et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler 2016; 22: 1550–1559. 2016/01/13.
Google Scholar | SAGE Journals | ISI34. Jakimovski, D, Kuhle, J, Ramanathan, M, et al. Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. Ann Clin Transl Neurol 2019; 6: 1757–1770. 2019/08/23.
Google Scholar | Crossref | Medline35. Canto, E, Barro, C, Zhao, C, et al. Association between Serum neurofilament light chain levels and long-term disease course Among patients With multiple sclerosis followed up for 12 years. JAMA Neurol 2019 Nov 1;76(11):1359-1366. 2019/08/14. DOI: 10.1001/jamaneurol.2019.2137.
Google Scholar | Crossref | Medline